ClinicalTrials.gg
WithdrawnNCT03359733Updated Feb 8, 2023

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

A Phase 1 interventional study of TAK-659 in Lymphoma, Malignant and Advanced Solid Neoplasms, sponsored by Calithera Biosciences, Inc. Withdrawn at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other

Why this study was withdrawn
Business decision: no safety or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,910 studies in Lymphoma with a site in United States — 162 open to participants now, 289 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
1,548th of 1,595
0 · median 36
Started
2018
with 58 others
Phase 1
582 of 1,910
38 open now
Registered
1,506th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 1,548th largest by enrollment of the 1,595 interventional ones that give a count, is one of 59 that started in 2018, is one of 582 in phase 1, and was the 1,506th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 435 are open to participants now.

Browse Lymphoma studies →

Open to participants now

162 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.

Read the detailed description

The drug being tested in this study is called TAK-659. TAK-659 is being tested in participants with advanced solid tumors and/or lymphomas in order to determine the effect of food on the PK of single oral dose of TAK-659 tablet formulation. The study will enroll approximately 20 participants. Participants will be randomly and equally assigned (by chance, like flipping a coin) to 1 of the 2 treatment sequences following as:

  • TAK-659 100 mg Fasted + TAK-659 100 mg Fed
  • TAK-659 100 mg Fed + TAK-659 100 mg Fasted

All participants will be asked to take single oral dose of TAK-659 tablet on Day 1 and Day 8 of a 15-day food effect treatment period. Upon completion of the food effect treatment period, participants can continue in the optional post food effect treatment period to receive TAK-659 100 mg, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicity, or the start of another anticancer therapy upon request by the investigator and agreement by the project clinician.

This single or multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 58 weeks. Participants will visit the clinic on Day -1 and remain confined until Day 15 of food effect treatment period. Participants will make a visit to the clinic after 28 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Lymphoma, Malignant
  • Advanced Solid Neoplasms

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a or cytologically confirmed and/or advanced solid tumor and/or lymphoma for which standard curative or life-prolonging treatment does not exist, or is no longer effective or tolerable.
  2. Has an (ECOG) performance status score of 0 or 1.
  3. Has a of at least 3 months.
  4. Suitable venous access for the study-required blood sampling (that is, PK).
  5. Must have adequate organ function, including the following:

    • Adequate bone marrow reserve: (ANC) greater than or equal to (>=) 1000 per cubic millimeter (/mm\^3), count >=75,000/ mm\^3 (>=50,000 per micro liter (/mcL) for participants with bone marrow involvement), and >=8 gram per deciliter (g/dL) (red blood cell [RBC] transfusion allowed >=14 days before assessment).
    • Hepatic: total less than or equal to (\<=) 1.5*the (ULN); (ALT) and aspartate aminotransferase (AST) \<=2.5*ULN.
    • Renal: serum creatinine \<=1.5*ULN or >=60 milliliter per minute (mL/min) as estimated by the Cockcroft-Gault equation or based on urine collection (12 or 24 hours).

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) lymphoma; active brain or , as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
  2. History of drug-induced pneumonitis requiring treatment with ; history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  3. Systemic anticancer treatment (including agents) less than 3 weeks before the first dose of study treatment (\<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agent; \<=8 weeks for cell-based therapy or anti-tumor vaccine).
  4. Radiotherapy less than 3 weeks before the first dose of study treatment.
  5. Use or consumption of any of the following substances:

    • Medications or supplements that are known to be inhibitors of P-glycoprotein (P-gp) and/or strong reversible inhibitors of cytochrome P450 (CYP) 3A within 5*the inhibitor half-life (if a reasonable half-life estimate is known), or within 7 days (if a reasonable half-life estimate is unknown), before the first dose of study drug.
    • Medications or supplements that are known to be strong mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days or within 5 times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drug. In general, the use of these agents is not permitted during the study except in cases in which an AE must be managed during interruption of study drug dosing.
    • Food or beverages containing grapefruit within 5 days before the first dose of study drug. Note that food and beverages containing grapefruit are not permitted during the study.
  6. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
  7. Active secondary that requires treatment. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.
  8. Lactose-intolerance or are unwilling/unable to consume the protocol-specified standardized high-fat, high-calorie breakfast.
  9. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659, including difficulty swallowing tablets or diarrhea greater than (>) Grade 1 despite supportive therapy.
  10. Treatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers are allowed.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TAK-659 100 mg Fasted + TAK-659 100 mg Fed

    TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.

    Drug: TAK-659

  • Experimental
    TAK-659 100 mg Fed + TAK-659 100 mg Fasted

    TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.

    Drug: TAK-659

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose

  2. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose

  3. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose

  4. Cmax: Maximum Observed Plasma Concentration for TAK-659

    Time frame: Day 8 pre-dose and at multiple time points (up to 168 hours) post-dose

  5. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-659

    Time frame: Day 8 pre-dose and at multiple time points (up to 168 hours) post-dose

  6. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-659

    Time frame: Day 8 pre-dose and at multiple time points (up to 168 hours) post-dose

Secondary outcomes

  1. Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  2. Percentage of Participants With Grade 3 or Above Adverse Event (AE)

    AE Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  3. Percentage of Participants With Drug-related AEs

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  4. Percentage of Participants With Drug-related Grade 3 or Above AEs

    AE Grades will be evaluated as per NCI CTCAE, version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  5. Percentage of Participants who Experience at Least 1 Serious Adverse Event (SAE)

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  6. Percentage of Participants who Discontinue due to an AE

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  7. Percentage of Participants who Meet the Takeda Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

  8. Percentage of Participants who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose

    Time frame: Baseline up to 28 days after the last dose of study drug (up to 58 weeks)

07

Study locations

3 sites
  • Yale Cancer Center
    New Haven, Connecticut 06519, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2018; primary completion for Jan 2019, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartEst.
Feb 28, 2018
Primary completionEst.
Jan 14, 2019
CompletionEst.
Aug 20, 2019
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03359733
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Feb 28, 2018 (estimated)
Primary completion
Jan 14, 2019 (estimated)
Completion
Aug 20, 2019 (estimated)
Last update
Feb 8, 2023

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-659

Start the discussion